The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 9 of 19
Back to Result List

Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma

  • Introduction: MDRO-colonization has been shown to impair survival in patients with hematological malignancies and solid tumors as well as in patients with liver disease. Despite the increasing spread of multidrug-resistant organisms (MDRO), its impact on patients with hepatocellular carcinoma (HCC) has not been studied. We conducted this retrospective study to analyze the impact of MDRO-colonization on overall prognosis in HCC patients. Materials and methods: All patients with confirmed HCC diagnosed between January 2008 and December 2017 at the University Hospital Frankfurt were included in this study. HCC patients with a positive MDRO screening before or within the first 90 days after diagnosis of HCC were defined as colonized HCC patients, HCC patients with a negative MDRO screening were defined as noncolonized HCC patients. Results: 59 (6%) colonized and 895 (94%) noncolonized HCC patients were included. Enterobacterales with extended-spectrum β-lactamase-like phenotype with or without resistance to fluoroquinolones (ESBL/ ± FQ) were the most frequently found MDRO with 59%, followed by vancomycin-resistant Enterococcus faecium with 37%. Colonized HCC patients had more severe cirrhosis and more advanced HCC stage compared to noncolonized HCC patients. Colonized HCC patients showed an impaired survival with a median OS of 189 days (6.3 months) compared to a median OS of 1001 days (33.4 months) in noncolonized HCC patients. MDRO-colonization was identified as an independent risk factor associated with survival in multivariate analysis. Conclusion: MDRO-colonization is an independent risk factor for survival in patients with HCC highlighting the importance of regular MDRO screening, isolation measures as well as interdisciplinary antibiotic steward-ship programs to guide responsible use of antibiotic agents.

Download full text files

Export metadata

Metadaten
Author:Vera HimmelsbachGND, Mate KnabeORCiD, Philip FerstlORCiDGND, Kai-Henrik PeifferORCiDGND, Jan Alexander StratmannGND, Thomas Alexander WichelhausORCiD, Michael HogardtORCiDGND, Volkhard A. J. KempfORCiDGND, Stefan ZeuzemORCiDGND, Oliver WaidmannORCiDGND, Fabian FinkelmeierORCiDGND, Olivier Karl Friedrich BalloORCiDGND
URN:urn:nbn:de:hebis:30:3-697591
DOI:https://doi.org/10.1007/s00432-021-03741-0
ISSN:1432-1335
Parent Title (English):Journal of cancer research and clinical oncology
Publisher:Springer
Place of publication:Berlin ; Heidelberg
Document Type:Article
Language:English
Date of Publication (online):2021/07/20
Date of first Publication:2021/07/20
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2023/03/03
Tag:Antibiotic steward-ship; Antibiotics; ESBL; Hepatocellular carcinoma; Infection; Liver cancer; Multidrug-resistant organisms; Survival; VRE
Volume:148
Issue:6
Page Number:8
First Page:1465
Last Page:1472
Note:
Open Access funding enabled and organized by Projekt DEAL.
HeBIS-PPN:507154371
Institutes:Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0